Inclusion Criteria:

- Patients with:

- Chronic lymphocytic leukemia (CLL) who are beyond first remission and who have
failed combination chemoimmunotherapy with regimens containing a purine analogue
and anti-CD20 antibody or who were not eligible for such therapy; patients with
fludarabine refractory disease are eligible

- Indolent non-Hodgkin lymphoma (NHL) or mantle cell NHL who are beyond first
remission and previously treated with chemoimmunotherapy; patients who have
relapsed following autologous hematopoietic cell transplantation (HCT) are
eligible

- Aggressive NHL such as diffuse large B-cell lymphoma (DLBCL) who have relapsed
or have residual disease following treatment with curative intent; patients must
have relapsed disease following high-dose therapy and autologous HCT or not be
candidates for high-dose therapy due to inability to collect autologous
peripheral blood stem cell (PBSC), advanced age or other co-morbid medical
conditions; patients with CD19 expressing, relapsed acute lymphoblastic leukemia
(ALL) without higher priority treatment options may be considered for inclusion
in this cohort after discussion with the principal investigator (PI)

- Confirmation of diagnosis by internal pathology review of initial or subsequent
biopsy or other pathologic material at the Fred Hutchinson Cancer Research Center
(FHCRC)/Seattle Cancer Care Alliance (SCCA)

- Evidence of CD19 expression by immunohistochemistry or flow cytometry on any prior or
current tumor specimen

- Karnofsky performance status > 70%

- Negative pregnancy test for women of childbearing potential

- All patients of childbearing potential must be willing to use a physician approved
contraceptive method before, during, and for at least two months after the T cell
infusion

- Ability to understand and provide informed consent

Exclusion Criteria:

- Treatment with other investigational agent(s) within 30 days of enrollment

- Patients requiring corticosteroid therapy at a dose of > 15 mg of prednisone per day
(or equivalent)

- Active autoimmune disease requiring immunosuppressive therapy

- Serum creatinine > 2.5 mg/dL

- Serum glutamic oxaloacetic transaminase (SGOT) > 5 x upper limit of normal

- Bilirubin > 3.0 mg/dL

- Forced expiratory volume in one second (FEV1) of < 2.0 L

- Diffusing capacity of the lung for carbon monoxide (DLCO) (corrected) < 40%

- Significant cardiovascular abnormalities as defined by any one of the following:
congestive heart failure, clinically significant hypotension, symptomatic coronary
artery disease, or a documented ejection fraction of < 35%

- Patients who are human immunodeficiency virus (HIV) seropositive or who have active
hepatitis B or C

- Men or women of reproductive ability who are unwilling to use effective contraception
or abstinence

- Uncontrolled active infection (bacterial, viral, fungal, mycobacterial) requiring
treatment with intravenous antibiotics, antiviral or antifungal agents, or long-term
treatment with oral agents

- Anticipated survival of < 3 months